🟢 IBRX is trading 4.5% up today after FDA accepts ANKTIVA expansion filing

IBRX is trading at $8.11 (+4.5%) after the FDA accepted ImmunityBio’s supplemental Biologics License Application (sBLA) for ANKTIVA.

• The filing seeks to expand the drug's use in combination with BCG for patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with papillary disease.
• This regulatory milestone serves as a significant company-specific catalyst, driving the stock's pre-market strength amid a generally firmer broader market.